Cited by 51Microtubule and mitosis dynamicsLung Cancer Research StudiesLung Cancer Treatments and Mutations

AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer

Open access
Al-Khafaji, Ahmed S.K., Marcus, Michael W., Davies, Michael P.A., Risk, Janet M., Shaw, Richard J., Field, John K., Liloglou, Triantafillos·2017·Oncology Letters

Abstract

Deregulation of mitotic spindle genes has been reported to contribute to the development and progression of malignant tumours. The aim of the present study was to explore the association between the expression profiles of Aurora kinases (AURKA, AURKB and AURKC), cytoskeleton‑associated protein 5 (CKAP5), discs large‑associated protein 5 (DLGAP5), kinesin‑like protein 11 (KIF11), microtubule nucleation factor (TPX2), monopolar spindle 1 kinase (TTK), and β‑tubulins (TUBB) and (TUBB3) genes and clinicopathological characteristics in human non‑small cell lung carcinoma (NSCLC). Reverse transcription-quantitative polymerase chain reaction‑based RNA gene expression profiles of 132 NSCLC and 44 adjacent wild‑type tissues were generated, and Cox's proportional hazard regression was used to examine associations. With the exception of AURKC, all genes exhibited increased expression in NSCLC tissues. Of the 10 genes examined, only AURKA was significantly associated with prognosis in NSCLC. Multivariate Cox's regression analysis demonstrated that AURKA mRNA expression [hazard ratio (HR), 1.81; 95% confidence interval (CI), 1.16‑2.84; P=0.009], age (HR, 1.03; 95% CI, 1.00‑1.06; P=0.020), pathological tumour stage 2 (HR, 2.43; 95% CI, 1.16‑5.10; P=0.019) and involvement of distal nodes (pathological node stage 2) (HR, 3.14; 95% CI, 1.24‑7.99; P=0.016) were independent predictors of poor prognosis in patients with NSCLC. Poor prognosis of patients with increased AURKA expression suggests that those patients may benefit from surrogate therapy with AURKA inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2017.6012

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Al-Khafaji, A. S. K., Marcus, M. W., Davies, M. P. A., Risk, J. M., Shaw, R. J., Field, J. K., & Liloglou, T.
Affiliations
  • University of Baghdad (IQ)
  • University of Liverpool (GB)
Venue
Oncology Letters
Published
2017-04-07
Volume
13
Issue
6
Pages
4463-4468
ISSN
  • 1792-1074 (ISSN-L)
  • 1792-1082
OpenAlex
W2604504944
Cited by
51
References
36
Citations by year
2026: 3 · 2025: 3 · 2024: 9 · 2023: 5 · 2022: 10 · 2021: 6 · 2020: 12 · 2018: 2 · 2017: 1
FWCI
2.19
Type
journal article
Language
en
Open access
Locations
  • Oncology Letters (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Edge Hill University Research Information Repository (Edge Hill University) (submittedVersion)
Funders
  • University of Baghdad
  • Roy Castle Lung Cancer Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
non-small cell lung cancer, AURKA, prognostic factors, gene expression profiling, TTK, TPX2, KIF11, DLGAP5, CKAP5, beta-tubulin, AURKA inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review